Psoriasis Club
  • Forum
  • Home
  • Portal
  • Member List
  • Psoriasis Score
  • PQOLS
  • What is psoriasis
  • Search
  • Help
Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members have more privileges)
wave
Login Register
Login
Username:
Password:
Lost Password?
 
Psoriasis Club › HealthHealth Boards › Psoriasis In The News v
1 2 3 4 5 … 49 Next »

Spevigo patient reported outcomes with pustular psoriasis

Threaded Mode
Spevigo patient reported outcomes with pustular psoriasis
Fred Offline
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 57,003
Threads: 3,553
Joined: Aug 2011
Gender: Male
Location: France
Psoriasis Score: 1
Psoriatic Arthritis Score: 1
PQOLS: 2
Treatment: Bimzelx / Coconut Oil
#1
News  Fri-30-12-2022, 15:07 PM
This study evaluated reported outcomes of patients with generalized pustular psoriasis (GPP) who were treated with Spevigo (spesolimab)

Quote:
Background:
Generalized pustular psoriasis (GPP) is a rare inflammatory skin disease with a considerable clinical burden. In the EffisayilTM 1 study, spesolimab, an anti-interleukin-36 receptor monoclonal antibody, demonstrated efficacy in treating GPP flares.

Objectives:
To evaluate patient-reported outcomes (PROs) of patients with GPP who were treated with intravenous (IV) spesolimab 900 mg in the EffisayilTM 1 study.

Methods:
53 patients presenting with a GPP flare were randomized (2:1) to receive a single dose of IV spesolimab 900 mg or placebo and were followed for 12 weeks. Four PROs [pain visual analog scale (pain VAS); Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT–Fatigue); Dermatology Life Quality Index (DLQI); and Psoriasis Symptom Scale (PSS)] were assessed throughout the 12-week study. Minimal clinically important differences (MCIDs) were defined. All data are reported descriptively.
Results

In patients who received spesolimab, improvements from baseline (median [Q1, Q3]) were observed in pain VAS (–21.3 [–55.3, –3.1]), FACIT–Fatigue (7.0 [1.0, 20.0]), DLQI (–2.5 [–8.0, 1.0]), and PSS (−4.0 [−7.0, 0.0]) within 1 week of treatment. These improvements were sustained over 12 weeks and corresponded to the achievement of MCIDs at Week 1, which were also sustained over 12 weeks. Patients in the placebo arm experienced improvements in PROs and achievement of MCIDs after receipt of open-label spesolimab at Week 1.

Conclusions:
Patients with a GPP flare treated with spesolimab achieved improvements in PROs by Week 1, which were sustained for 12 weeks, and achieved MCIDs as early as Week 1.

Source: onlinelibrary.wiley.com

*Early view funding unknown

Spevigo (spesolimab)
Quote
« Next Oldest | Next Newest »


Possibly Related Threads…
Thread Author Replies Views Last Post
News Assessing severity of pustular psoriasis Fred 0 377 Sat-04-03-2023, 12:01 PM
Last Post: Fred
News Delphi study into generalized pustular psoriasis Fred 0 416 Sat-07-01-2023, 14:17 PM
Last Post: Fred
News FDA approves Spevigo for pustular psoriasis Fred 6 1,548 Wed-14-12-2022, 14:29 PM
Last Post: Fred
News Ventyx gives first dose of VTX958 to psoriasis patient Fred 2 631 Mon-05-12-2022, 16:06 PM
Last Post: Fred
News Spesolimab IL-36 for pustular psoriasis Fred 2 1,158 Sat-25-12-2021, 16:56 PM
Last Post: Wooley



Users browsing this thread: 1 Guest(s)
    Contact us | Login | Register | Home | Cookies/GDPR | RSS Syndication | Portal | Types Of Psoriasis | Psoriasis Score | Members Only Boards
    Copyright © 2010 - 2023 Psoriasis Club All Rights Reserved | Founded May 2010 | Psoriasis Club Is Self Funded Without Sponsors Or Donations | Software by MyBB | Social
Linear Mode
Threaded Mode